Avalanche Eye Gene Therapy Meets Safety Goal

Avalanche Biotechnologies Inc's experimental gene therapy for a leading cause of blindness met its primary safety goal in a small mid-stage trial, while staving off vision loss.
Reuters Health Information

Full Story →